What diseases does Trametinib treat?

Trametinib (Trametinib) is a targeted therapy drug mainly used to treat specific types of cancer. For example, trametinib combined with other drugs (such as dabrafenib) can be used to treat untreated metastatic non-small cell lung cancer (NSCLC) with BRAF V600E gene mutations, and to treat malignant melanoma (skin cancer) that is unresectable or has metastasized BRAF V600E or V600K mutation-positive malignant melanoma (skin cancer). Trametinib is only effective in patients with specific genetic mutations, and before determining whether trametinib is a candidate for use, doctors typically perform genetic testing to determine whether the drug is appropriate for a patient's individual situation. Due to known inherent resistance to BRAF inhibition, trametinib is not indicated for the treatment of patients with colorectal cancer.

The original drug of trametinib has been launched in China and has entered the scope of Class B medical insurance, but it may only be purchased by patients who meet the indications of trametinib, such as BRAF V600 mutation-positive unresectable or metastatic melanoma. Its price is around 10,000 to 20,000 yuan. The reimbursement ratio is different in different regions, and the price is also different, making it expensive. The price of the Turkish version of the original drug Trametinib listed overseas is around RMB 7,900 (the price may fluctuate due to the exchange rate). Generic trametinib is also produced in other countries. The price of the Lao pharmaceutical factory is around RMB 2,950 (the price may fluctuate due to the exchange rate). The ingredients and efficacy of foreign generic drugs are basically the same as those of domestic and foreign original drugs.